The skeletal morbidity rate was slightly lower in patients treated with zoledronic acid than in those treated with pamidronate , and zoledronic acid ( 4 mg ) significantly decreased the incidence and event rate for radiation therapy to bone , both overall and in breast cancer patients receiving hormonal therapy .
